Section Edited by Ignacio Melero, MD, PhD and Alexandra Snyder Charen, MD
Consisting of predictive/prognostic biomarker studies, gene expression studies in cancer immunotherapy, serological immune biomarkers, multiparameter flow cytometry-defined immune biomarkers, high content immunohistological studies, clinical trial analyses and identification of novel immune biomarkers. Manuscripts will be prioritized for peer review and publication on the basis of innovation/novelty of the biomarker-oriented research, adequate validation, clinical relevance and technological novelty.
Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanomaJudith M Versluis, Stephanie A Blankenstein, Petros Dimitriadis, James S Wilmott, Robert Elens, Willeke A M Blokx, Winan van Houdt, Alexander Maxwell Menzies, Yvonne M Schrage, Michel W J M Wouters, Joyce Sanders, Annegien Broeks, Richard A Scolyer, Karijn P M Suijkerbuijk, Georgina V LongSee the full list of authors
27 April 2024
Total metabolic tumor volume on F-FDG PET/CT is a game-changer for patients with metastatic lung cancer treated with immunotherapyPierre Tricarico, David Chardin, Nicolas Martin, Sara Contu, Florent Hugonnet, Josiane Otto, Olivier Humbert
22 April 2024
Tumor-agnostic transcriptome-based classifier identifies spatial infiltration patterns of CD8+T cells in the tumor microenvironment and predicts clinical outcome in early-phase and late-phase clinical trialsAndreas Roller, Iakov I Davydov, Petra C Schwalie, Martha L Serrano-Serrano, Astrid Heller, Nicolas Staedler, Cláudia S Ferreira, Gabriele Dietmann, Irina Klaman, Alberto Valdeolivas, Konstanty Korski, Michael A Cannarile
22 April 2024
Dysregulation of CD4 and CD8 resident memory T, myeloid, and stromal cells in steroid-experienced, checkpoint inhibitor colitisJun Yan He, Yang-Joon Kim, Elvira Mennillo, Iulia Rusu, Jared Bain, Arjun A Rao, Christopher Andersen, Karen Law, Hai Yang, Jessica Tsui, Alan Shen, Brittany Davidson, Divyashree Kushnoor, Yimin Shi, Frances FanSee the full list of authors
19 April 2024
Association of metabolomics with PD-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancerLiang Zheng, Fang Hu, Lin Huang, Jun Lu, Xiaohua Yang, Jianlin Xu, Shuyuan Wang, Yinchen Shen, Runbo Zhong, Tianqing Chu, Wei Zhang, Ying Li, Xiaoxuan Zheng, Baohui Han, Hua ZhongSee the full list of authors
18 April 2024
Spatial comparison of molecular features associated with resistance to pembrolizumab in BCG unresponsive bladder cancerKhyati Meghani, Noah Frydenlund, Yanni Yu, Bonnie Choy, Joshua J Meeks
16 April 2024
Oral PD-L1 inhibitor GS-4224 selectively engages PD-L1 high cells and elicits pharmacodynamic responses in patients with advanced solid tumorsJared M Odegard, Ahmed A Othman, Kai-Wen Lin, Adele Y Wang, Jonathan Nazareno, Oh Kyu Yoon, John Ling, Latesh Lad, P Rod Dunbar, Dung Thai, Edmond Ang, Nicholas Waldron, Sanjeev Deva
11 April 2024
OMA1 competitively binds to HSPA9 to promote mitophagy and activate the cGAS–STING pathway to mediate GBM immune escapeWen de Zhu, Jin Rao, Li hua Zhang, Ka ming Xue, Lin Li, Jun jun Li, Qian zhi Chen, Rong Fu
11 April 2024
Preclinical development of novel PD-L1 tracers and first-in-human study of [Ga]Ga-NOTA-RW102 in patients with lung cancersYou Zhang, Min Cao, Yanfei Wu, Sara Malih, Dong Xu, Erpeng Yang, Muhsin H Younis, Wilson Lin, Haitao Zhao, Cheng Wang, Qiufang Liu, Jonathan W Engle, Mohammad J Rasaee, Yihui Guan, Gang HuangSee the full list of authors
5 April 2024
Digital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanomaDavid G Su, David A. Schoenfeld, Wael Ibrahim, Raysa Cabrejo, Dijana Djureinovic, Raymond Baumann, David L Rimm, Sajid A Khan, Ruth Halaban, Harriet M Kluger, Kelly Olino, Anjela Galan, James Clune
21 March 2024